# CBER

Type: organization

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/cber-organization
Canonical HTML page: https://gethealthbrief.com/entity/cber-organization

## Timeline

- **2026-03**: Final Departure — Official announcement of Marks leaving the agency for the second time.
- **2025**: Initial Friction — Reports surface of Marks considering resignation amid administrative policy shifts.
- **2020**: Operation Warp Speed — Plays a central role in the emergency use authorizations for COVID-19 vaccines.
- **2016**: Appointed Director — Promoted to Director of CBER, overseeing the 'Gold Standard' of vaccine review.
- **2012**: Joins FDA — Dr. Peter Marks joins the FDA as Deputy Director of CBER.

## Recent coverage (1 stories)

### FDA Vaccine Chief Departs Amid Regulatory Overhaul and Political Pressure
2026-03-07 01:51:00 · Sentiment: Negative · Impact: 6/10 · Sources: 6

Dr. Peter Marks, the long-serving head of the FDA’s vaccine division, is stepping down for the second time as the Trump administration intensifies its 'Make America Healthy Again' initiatives. His exit marks a critical turning point for the Center for Biologics Evaluation and Research and signals a potential shift in the agency's rigorous approval standards.
Full story: https://gethealthbrief.com/story/fda-vaccine-chief-departure-trump-administration

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.